NASDAQ:AUPHAurinia Pharmaceuticals Stock Price, Forecast & News Adding Choose a watchlist: Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat Daily Premium to add more stocks to your watchlist. Adding Aurinia Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Log In and Add $14.03 -0.15 (-1.06 %) (As of 08/13/2020 11:13 AM ET) Add Compare Share Today's Range$13.92Now: $14.03▼$14.3050-Day Range$13.19MA: $14.82▼$16.6652-Week Range$3.52Now: $14.03▼$21.93Volume14,268 shsAverage Volume1.59 million shsMarket Capitalization$1.77 billionP/E RatioN/ADividend YieldN/ABeta1.18 ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInstitutional OwnershipHeadlinesOptions ChainSEC FilingsShort InterestSocial Media Aurinia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, engages in the research, development, and commercialization of therapeutic drugs for the treatment of various diseases in the United States and China. The company is involved in developing voclosporin, an investigational drug for the treatment of lupus nephritis, dry eye syndrome, and focal segmental glomerulosclerosis. Aurinia Pharmaceuticals Inc. is headquartered in Victoria, Canada.Read More Beat the Market (BTM) Rank™ 3.5 Analyst's Opinion Consensus RatingAurinia Pharmaceuticals has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 9 buy ratings, no hold ratings, and no sell ratings.Price Target Upside/DownsideAccording to analysts' consensus price target of $24.00, Aurinia Pharmaceuticals has a potential upside of 71.4% from its current price of $14.00.Amount of Analyst CoverageAurinia Pharmaceuticals has only been the subject of 3 research reports in the past 90 days. Previous Next 3.0 Community Rank Outperform VotesAurinia Pharmaceuticals has received 523 “outperform” votes. (Add your “outperform” vote.)Underperform VotesAurinia Pharmaceuticals has received 341 “underperform” votes. (Add your “underperform” vote.)Community SentimentAurinia Pharmaceuticals has received 60.53% “outperform” votes from our community.MarketBeat's community ratings are surveys of what our community members think about Aurinia Pharmaceuticals and other stocks. Vote “Outperform” if you believe AUPH will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AUPH will underperform the S&P 500 over the long term. You may vote once every thirty days. Previous Next 0.0 Dividend Strength Dividend YieldAurinia Pharmaceuticals does not currently pay a dividend.Dividend GrowthAurinia Pharmaceuticals does not have a long track record of dividend growth. Previous Next 1.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Aurinia Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by Institutions53.49% of the stock of Aurinia Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Aurinia Pharmaceuticals are expected to grow in the coming year, from ($0.90) to ($0.69) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Aurinia Pharmaceuticals is -10.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Aurinia Pharmaceuticals is -10.69, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAurinia Pharmaceuticals has a P/B Ratio of 5.71. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities. Previous Next Analyst Opinion: 3.5Community Rank: 3.0Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 0.6 5 -4 -3 -2 -1 -Overall Beat the Market Rank™1.63 out of 5 stars Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:AUPH Previous Symbol CUSIPN/A CIK1600620 Webwww.auriniapharma.com Phone250-708-4272Debt Debt-to-Equity Ratio0.02 Current Ratio21.01 Quick Ratio21.01Price-To-Earnings Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/A Sales & Book Value Annual Sales$320,000.00 Price / Sales5,525.98 Cash FlowN/A Price / Cash FlowN/A Book Value$2.45 per share Price / Book5.73Profitability EPS (Most Recent Fiscal Year)($0.89) Net Income$-123,850,000.00 Net Margins-43,965.98% Return on Equity-40.66% Return on Assets-33.89%Miscellaneous Employees39 Outstanding Shares126,038,000Market Cap$1.77 billion Next Earnings Date11/12/2020 (Estimated) OptionableOptionable $14.03 -0.15 (-1.06 %) (As of 08/13/2020 11:13 AM ET) 30 days | 90 days | 365 days | Advanced Chart Receive AUPH News and Ratings via Email Sign-up to receive the latest news and ratings for AUPH and its competitors with MarketBeat's FREE daily newsletter. Aurinia Pharmaceuticals (NASDAQ:AUPH) Frequently Asked Questions How has Aurinia Pharmaceuticals' stock price been impacted by Coronavirus (COVID-19)? Aurinia Pharmaceuticals' stock was trading at $14.10 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization (WHO). Since then, AUPH stock has decreased by 0.4% and is now trading at $14.05. View which stocks have been most impacted by COVID-19. Do Wall Street analysts recommend investors buy shares of Aurinia Pharmaceuticals? 9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Aurinia Pharmaceuticals in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Aurinia Pharmaceuticals. When is Aurinia Pharmaceuticals' next earnings date? Aurinia Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Thursday, November 12th 2020. View our earnings forecast for Aurinia Pharmaceuticals. How were Aurinia Pharmaceuticals' earnings last quarter? Aurinia Pharmaceuticals Inc (NASDAQ:AUPH) released its earnings results on Tuesday, August, 11th. The biotechnology company reported ($0.26) EPS for the quarter, missing the Thomson Reuters' consensus estimate of ($0.23) by $0.03. Aurinia Pharmaceuticals had a negative net margin of 43,965.98% and a negative return on equity of 40.66%. View Aurinia Pharmaceuticals' earnings history. What price target have analysts set for AUPH? 9 Wall Street analysts have issued 1-year price objectives for Aurinia Pharmaceuticals' stock. Their forecasts range from $14.00 to $34.00. On average, they anticipate Aurinia Pharmaceuticals' stock price to reach $24.00 in the next twelve months. This suggests a possible upside of 70.8% from the stock's current price. View analysts' price targets for Aurinia Pharmaceuticals. Has Aurinia Pharmaceuticals been receiving favorable news coverage? Media coverage about AUPH stock has been trending extremely negative on Thursday, InfoTrie Sentiment Analysis reports. The research firm scores the sentiment of news coverage by analyzing more than six thousand news and blog sources in real time. The firm ranks coverage of companies on a scale of -5 to 5, with scores closest to five being the most favorable. Aurinia Pharmaceuticals earned a news impact score of -4.1 on InfoTrie's scale. They also assigned news stories about the biotechnology company a news buzz of 10.0 out of 10, meaning that recent news coverage is extremely likely to have an effect on the company's share price in the near term. View the latest news about Aurinia Pharmaceuticals. Are investors shorting Aurinia Pharmaceuticals? Aurinia Pharmaceuticals saw a decrease in short interest in February. As of February 15th, there was short interest totaling 4,510,000 shares, a decrease of 11.9% from the January 31st total of 5,120,000 shares. Based on an average daily volume of 3,510,000 shares, the short-interest ratio is presently 1.3 days. Approximately 5.5% of the shares of the stock are short sold. View Aurinia Pharmaceuticals' Short Interest. Who are some of Aurinia Pharmaceuticals' key competitors? Some companies that are related to Aurinia Pharmaceuticals include Jazz Pharmaceuticals (JAZZ), Emergent Biosolutions (EBS), ACADIA Pharmaceuticals (ACAD), Bausch Health Companies (BHC), Mirati Therapeutics (MRTX), Myokardia (MYOK), Ultragenyx Pharmaceutical (RARE), United Therapeutics (UTHR), Zai Lab (ZLAB), HUTCHISON CHINA/S (HCM), Schrodinger (SDGR), Allakos (ALLK), Blueprint Medicines (BPMC), Arrowhead Pharmaceuticals (ARWR) and Evotec (EVTCY). View all competitors. What other stocks do shareholders of Aurinia Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some companies that other Aurinia Pharmaceuticals investors own include Tetraphase Pharmaceuticals (TTPH), NVIDIA (NVDA), Micron Technology (MU), Advanced Micro Devices (AMD), Cara Therapeutics (CARA), Exelixis (EXEL), Sorrento Therapeutics (SRNE), Array Biopharma (ARRY), Alibaba Group (BABA) and Corbus Pharmaceuticals (CRBP). Who are Aurinia Pharmaceuticals' key executives? Aurinia Pharmaceuticals' management team includes the following people: Mr. Michael R. Martin, Co-Founder & COOMr. Dennis Bourgeault CPA, C.A., CFO & Sec.Mr. Robert B. Huizinga RN NNC, MSc(Epi), CNeph(C), Exec. VP of Corp. Devel.Dr. Richard M. Glickman, Advisor (Age 61)Dr. Neil Solomons M.D., Chief Medical Officer What is Aurinia Pharmaceuticals' stock symbol? Aurinia Pharmaceuticals trades on the NASDAQ under the ticker symbol "AUPH." Who are Aurinia Pharmaceuticals' major shareholders? Aurinia Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional shareholders include Assenagon Asset Management S.A. (0.79%), Hudson Bay Capital Management LP (0.30%), Goldman Sachs Group Inc. (0.21%), Bank of Montreal Can (0.17%), Swiss National Bank (0.14%) and BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp (0.13%). Which institutional investors are selling Aurinia Pharmaceuticals stock? AUPH stock was sold by a variety of institutional investors in the last quarter, including Goldman Sachs Group Inc., Assenagon Asset Management S.A., Hudson Bay Capital Management LP, UBS Group AG, and Patriot Financial Group Insurance Agency LLC. Which institutional investors are buying Aurinia Pharmaceuticals stock? AUPH stock was purchased by a variety of institutional investors in the last quarter, including Bank of Montreal Can, BRITISH COLUMBIA INVESTMENT MANAGEMENT Corp, Alps Advisors Inc., Knott David M, CIBC Asset Management Inc, Bailard Inc., Swiss National Bank, and Ensign Peak Advisors Inc. How do I buy shares of Aurinia Pharmaceuticals? Shares of AUPH can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab. What is Aurinia Pharmaceuticals' stock price today? One share of AUPH stock can currently be purchased for approximately $14.05. How big of a company is Aurinia Pharmaceuticals? Aurinia Pharmaceuticals has a market capitalization of $1.77 billion and generates $320,000.00 in revenue each year. The biotechnology company earns $-123,850,000.00 in net income (profit) each year or ($0.89) on an earnings per share basis. Aurinia Pharmaceuticals employs 39 workers across the globe. What is Aurinia Pharmaceuticals' official website? The official website for Aurinia Pharmaceuticals is www.auriniapharma.com. How can I contact Aurinia Pharmaceuticals? Aurinia Pharmaceuticals' mailing address is 4464 MARKHAM STREET SUITE 1203, VICTORIA A1, V8Z 7X8. The biotechnology company can be reached via phone at 250-708-4272 or via email at [email protected] This page was last updated on 8/13/2020 by MarketBeat.com Staff 30 Days of MarketBeat All Access for $1.00 Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your Risk-Free Trial Subscription Here Questions? Get Started with MarketBeat — Read Your Daily NewsletterCheck Out My MarketBeatWatch Our Tutorial VideosAdd a Stock to Your WatchlistSet Up an Instant AlertView a Company's Profile PageView Our Financial CalendarsView Today's Analyst Ratings
